Cara Therapeutics, Inc is a biotechnology business based in the US. Cara Therapeutics shares (CARA) are listed on the NASDAQ and all prices are listed in US Dollars. Cara Therapeutics employs 80 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Cara Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CARA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- CARA shares summary
- Compare share dealing platforms
- Is CARA stock a buy or sell?
- Stock performance over time
- Can I short CARA shares?
- Are CARA shares over-valued?
- Cara Therapeutics's financials
- How volatile are CARA shares?
- Does Cara Therapeutics pay a dividend?
- Have CARA shares ever split?
- Other common questions
Cara Therapeutics stock price (NASDAQ: CARA)Use our graph to track the performance of CARA stocks over time.
Cara Therapeutics shares at a glance
|Latest market close||$13.00|
|52-week range||$11.80 - $29.65|
|50-day moving average||$13.87|
|200-day moving average||$17.82|
|Wall St. target price||$27.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.29|
Buy Cara Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Cara Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cara Therapeutics price performance over time
|1 week (2021-07-17)||N/A|
|1 month (2021-06-28)||-10.53%|
|3 months (2021-04-28)||-49.59%|
|6 months (2021-01-24)||N/A|
|1 year (2020-07-24)||N/A|
|2 years (2019-07-24)||N/A|
|3 years (2018-07-24)||N/A|
|5 years (2016-07-24)||N/A|
Is Cara Therapeutics under- or over-valued?
Valuing Cara Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cara Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cara Therapeutics's P/E ratio
Cara Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 43x. In other words, Cara Therapeutics shares trade at around 43x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cara Therapeutics's EBITDA
Cara Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $12 million.
The EBITDA is a measure of a Cara Therapeutics's overall financial performance and is widely used to measure a its profitability.
Cara Therapeutics financials
|Revenue TTM||$128.9 million|
|Operating margin TTM||9.17%|
|Gross profit TTM||$27.2 million|
|Return on assets TTM||3.31%|
|Return on equity TTM||7.18%|
|Market capitalisation||$631.2 million|
TTM: trailing 12 months
Shorting Cara Therapeutics shares
There are currently 3.2 million Cara Therapeutics shares held short by investors – that's known as Cara Therapeutics's "short interest". This figure is 10.4% down from 3.5 million last month.
There are a few different ways that this level of interest in shorting Cara Therapeutics shares can be evaluated.
Cara Therapeutics's "short interest ratio" (SIR)
Cara Therapeutics's "short interest ratio" (SIR) is the quantity of Cara Therapeutics shares currently shorted divided by the average quantity of Cara Therapeutics shares traded daily (recently around 623508.25147348). Cara Therapeutics's SIR currently stands at 5.09. In other words for every 100,000 Cara Therapeutics shares traded daily on the market, roughly 5090 shares are currently held short.
However Cara Therapeutics's short interest can also be evaluated against the total number of Cara Therapeutics shares, or, against the total number of tradable Cara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cara Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Cara Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0751% of the tradable shares (for every 100,000 tradable Cara Therapeutics shares, roughly 75 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cara Therapeutics.
Find out more about how you can short Cara Therapeutics stock.
Cara Therapeutics share dividends
We're not expecting Cara Therapeutics to pay a dividend over the next 12 months.
Have Cara Therapeutics's shares ever split?
Cara Therapeutics's shares were split on a 1:2 basis on 15 January 2014. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cara Therapeutics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Cara Therapeutics shares which in turn could have impacted Cara Therapeutics's share price.
Cara Therapeutics share price volatility
Over the last 12 months, Cara Therapeutics's shares have ranged in value from as little as $11.8 up to $29.6473. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cara Therapeutics's is 1.1017. This would suggest that Cara Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cara Therapeutics overview
Cara Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co.
Stocks similar to Cara Therapeutics
Cara Therapeutics in the news
First Week of February 2022 Options Trading For Cara Therapeutics
Noteworthy Tuesday Option Activity: TSCO, CARA, MARA
Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive
Frequently asked questionsWhat percentage of Cara Therapeutics is owned by insiders or institutions?
Currently 10.5% of Cara Therapeutics shares are held by insiders and 68.512% by institutions. How many people work for Cara Therapeutics?
Latest data suggests 80 work at Cara Therapeutics. When does the fiscal year end for Cara Therapeutics?
Cara Therapeutics's fiscal year ends in December. Where is Cara Therapeutics based?
Cara Therapeutics's address is: 4 Stamford Plaza, Stamford, CT, United States, 06902 What is Cara Therapeutics's ISIN number?
Cara Therapeutics's international securities identification number is: US1407551092 What is Cara Therapeutics's CUSIP number?
Cara Therapeutics's Committee on Uniform Securities Identification Procedures number is: 140755109
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy HNC Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert